Trading of Clearside Biomedical was halted at 10:37 AM EST due to "LULD pause". Clearside Biomedical (CLSD) Competitors $0.55 -0.29 (-34.45%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLSD vs. ACB, IMMP, NBTX, FENC, TKNO, EDIT, SCPH, ELDN, ESPR, and TVGNShould you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Aurora Cannabis (ACB), Prima BioMed (IMMP), Nanobiotix (NBTX), Adherex Technologies (FENC), Alpha Teknova (TKNO), Editas Medicine (EDIT), scPharmaceuticals (SCPH), Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry. Clearside Biomedical vs. Its Competitors Aurora Cannabis Prima BioMed Nanobiotix Adherex Technologies Alpha Teknova Editas Medicine scPharmaceuticals Eledon Pharmaceuticals Esperion Therapeutics Semper Paratus Acquisition Clearside Biomedical (NASDAQ:CLSD) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Which has preferable earnings and valuation, CLSD or ACB? Aurora Cannabis has higher revenue and earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearside Biomedical$1.66M25.65-$34.35M-$0.41-1.34Aurora Cannabis$246.72M1.02$1.63M$0.1140.86 Do analysts recommend CLSD or ACB? Clearside Biomedical presently has a consensus price target of $4.75, suggesting a potential upside of 766.79%. Given Clearside Biomedical's higher possible upside, analysts clearly believe Clearside Biomedical is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearside Biomedical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Does the media favor CLSD or ACB? In the previous week, Clearside Biomedical and Clearside Biomedical both had 5 articles in the media. Clearside Biomedical's average media sentiment score of 1.89 beat Aurora Cannabis' score of 0.55 indicating that Clearside Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clearside Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aurora Cannabis 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CLSD or ACB? Clearside Biomedical has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Do insiders and institutionals have more ownership in CLSD or ACB? 18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 6.2% of Clearside Biomedical shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is CLSD or ACB more profitable? Aurora Cannabis has a net margin of 1.32% compared to Clearside Biomedical's net margin of -818.57%. Aurora Cannabis' return on equity of 0.13% beat Clearside Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Clearside Biomedical-818.57% N/A -114.23% Aurora Cannabis 1.32%0.13%0.10% SummaryAurora Cannabis beats Clearside Biomedical on 10 of the 16 factors compared between the two stocks. Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLSD vs. The Competition Export to ExcelMetricClearside BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.82M$2.93B$5.52B$9.35BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-1.1220.5927.9519.83Price / Sales25.65289.89438.79106.18Price / CashN/A42.3835.5357.53Price / Book-1.077.788.255.72Net Income-$34.35M-$55.11M$3.23B$257.51M7 Day Performance-37.41%1.31%-0.13%0.59%1 Month Performance-30.63%11.91%7.21%10.74%1 Year Performance-54.71%0.19%27.45%15.87% Clearside Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLSDClearside Biomedical2.075 of 5 stars$0.55-34.4%$4.75+766.8%-31.5%$35.82M$1.66M-1.1230News CoveragePositive NewsTrading HaltedHigh Trading VolumeACBAurora Cannabis0.3647 of 5 stars$4.58+2.0%N/A-27.9%$257.44M$246.72M41.641,130IMMPPrima BioMed1.5022 of 5 stars$1.69+2.4%$7.00+314.2%-19.2%$246.81M$5.14M0.002,021Positive NewsNBTXNanobiotix2.6401 of 5 stars$5.15-0.4%$8.00+55.3%-4.5%$242.72M$39.18M0.00100FENCAdherex Technologies2.2743 of 5 stars$8.79+0.1%$13.00+47.9%+32.5%$242.60M$47.54M-17.2410TKNOAlpha Teknova1.8739 of 5 stars$4.49-6.7%$12.00+167.3%+219.3%$239.95M$38.25M-9.35240Positive NewsEDITEditas Medicine4.2389 of 5 stars$2.85-1.0%$4.70+64.9%-52.3%$238.57M$32.31M-0.94230News CoveragePositive NewsSCPHscPharmaceuticals4.3897 of 5 stars$4.48+2.3%$14.00+212.5%-10.8%$236.50M$36.33M-2.3530Positive NewsELDNEledon Pharmaceuticals1.9909 of 5 stars$3.91+14.3%$9.00+130.2%+33.6%$234.13MN/A-1.8610Analyst RevisionGap UpHigh Trading VolumeESPREsperion Therapeutics3.9476 of 5 stars$1.18-0.8%$7.00+493.2%-59.0%$233.88M$332.31M-1.47200Analyst RevisionTVGNSemper Paratus Acquisition4.1186 of 5 stars$1.26+5.9%$10.00+693.7%+68.5%$231.70MN/A0.003News Coverage Related Companies and Tools Related Companies Aurora Cannabis Competitors Prima BioMed Competitors Nanobiotix Competitors Adherex Technologies Competitors Alpha Teknova Competitors Editas Medicine Competitors scPharmaceuticals Competitors Eledon Pharmaceuticals Competitors Esperion Therapeutics Competitors Semper Paratus Acquisition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLSD) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
